The evolution of cancer research and drug discovery at Lilly Research Laboratories

Advances in Enzyme Regulation

Volumn 45, Issue 1, 2005, Pages 229-255

  Pearce, Homer L ^a   Alice Miller, Mary ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VINCA;

EID: 28444476566     PISSN: 00652571     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.advenzreg.2005.02.017     Document Type: Article

References (82)

1. ®): a novel multitargeted antifolate agent Expert Rev Anticancer Ther 3 2003 145 155
2. A.A. Adjei, C. Erlichman, J.A. Sloan, J.M. Reid, H.C. Pitot, R.M. Goldberg, P. Peethambaram, P. Atherton, L.J. Hanson, S.R. Alberts, and J. Jett Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors J Clin Oncol 18 2000 1748 1757
3. T. Alati, J.F. Worzalla, C. Shih, J.R. Bewley, S. Lewis, R.G. Moran, and G.B. Grindey Augmentation of the therapeutic activity of lometrexol - (6-R)5,10-dideazatetrahydrofolate - by oral folic acid Cancer Research 56 1996 2331 2335
4. K.S. Albain, S. Nag, G. Calderillo-Ruiz, J.P. Jordaan, A. Llombart, A. Pluzanska, M. Pawlicki, A.S. Melemed, J. O'Shaughnessy, and J.M. Reyes Global phase III study of gemcitabine plus paclitaxel (GT) vs paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall survival Proc Am Soc Clin Oncol 22 2004 14S (abstr 510)
5. R.H. Allen, S.P. Stabler, D.G. Savage, and J. Lindenbaum Metabolic abnormalities in cobalamin (vitamin B12) and folate deficiency FASEB J 7 1993 1344 1353
6. H.H. Backus, H.M. Pinedo, D. Wouters, C.M. Kuiper, G. Jansen, C.J. van Groeningen, and G.J. Peters Differences in the induction of DNA damage, cell cycle arrest, and cell death by 5-fluorouracil and antifolates Oncol Res 12 2000 231 239
7. W.T. Bellamy, L. Richter, Y. Frutiger, and T.M. Grogan Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies Cancer Res 59 1999 728 733
8. C.D. Britten, A.E. Izbicka, R. Lawrence, K. Davidson, C. Cerna, L. Gomez, E.K. Rowinsky, S. Weitman, and D.D. Von Hoff Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay Cancer Chemother Pharmacol 44 1999 105 110
9. J.H. Burchenal, B. Leyland-Jones, K. Watanabe, R. Klein, C. Lopez, and J.J. Fox Experimental and clinical studies of 2′-flu-oroarabinosyl- pyrimidines and purinelike C-nucleosides J.L. Rideout D.W. Henry L.M. Beacham III Proceedings of the fifth international roundtable on nucleosides, nucleotides, and their biological applications 1983 Academic Press New York 47 65
10. H. Burris, and A.M. Storniolo Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil Eur J Cancer 33 suppl 1 1997 S18 S22
11. H. Calvert An overview of folate metabolism: features relevant to the action and toxicities of antifolate anticancer agents Semin Oncol 26 suppl 6 1999 3 10
12. A. Calvert, A.N. Hughes, P.M. Calvert, R.E. Plummer, and M.S. Highley ALIMTA™ in combination with carboplatin demonstrates clinical activity against malignant mesothelioma in a phase I trial Lung Cancer 29 suppl 1 2000 19 20
13. F. Cardenal, M.P. Lopez-Cabrerizo, A. Anton, V. Alberola, B. Massuti, A. Carrato, I. Barneto, M. Lomas, M. Garcia, P. Lianes, J. Montalar, C. Vadell, J.L. Gonzalez-Larriba, B. Nguyen, A. Artal, and R. Rosell Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer J Clin Oncol 17 1999 12 18
14. K.P. Claffey, and G.S. Robinson Regulation of VEGF/VPF expression in tumor cells: consequences for tumor growth and metastases Cancer Metastasis Rev 15 1996 165 176
15. M.M. Faul, J.L. Grutsch, M.E. Kobierski, M.E. Kopach, C.A. Krumrich, M.A. Staszak, U. Udodong, J.T. Vicenzi, and K.A. Sullivan Strategies for the synthesis of N-(azacycloalkyl)bisindolylmaleimides: Selective inhibitors of PKCβ Tetrahedron 59 2003 7215 7229
16. M.M. Faul, M.E. Kobierski, and M.E. Kopach Green chemistry approach to the synthesis of N-substituted piperidones J Org Chem 68 2003 5739 5741
17. N. Ferrara, and K. Alitalo Clinical applications of angiogenic growth factors and their inhibitors Nat Med 5 1999 1359 1364
18. N. Ferrara, and W.J. Henzel Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells Biochem Biophys Res Commun 161 1989 851 858
19. N. Ferrara, K.A. Houck, L.B. Jakeman, and D.W. Leung Molecular and biological properties of the vascular endothelial growth factor family of proteins Endocr Rev 13 1992 18 32
20. J. Folkman Tumor angiogenesis: therapeutic implications N Engl J Med 285 1971 1182 1186
21. S.B. Gates, L.G. Mendelsohn, K.A. Shackelford, L.L. Habeck, J.D. Kursar, L.S. Gossett, J.F. Worzalla, C. Shih, and G.B. Grindey Characterization of folate receptor from normal and neoplastic murine tissue: influence of dietary folate on folate receptor expression Clin Cancer Res 2 1996 1135 1141
22. S.B. Gates, J.F. Worzalla, C. Shih, G.B. Grindey, and L.G. Mendelsohn Dietary folate and folylpolyglutamate synthetase activity in normal and neoplastic murine tissues and human tumor xenografts Biochem Pharmacol 52 1996 1477 1479
23. Gemzar [package insert]. Indianapolis, IN: Eli Lilly and Company; 2004.
24. M.A. Gimbrone Jr., S.B. Leapman, R.S. Cotran, and J. Folkman Tumor dormancy in vivo by prevention of neovascularization J Exp Med 136 1972 261 276
25. C.H. Graham, J. Rivers, R.S. Kerbel, K.S. Stankiewicz, and W.L. White Extent of vascularization as a prognostic indicator in thin (<0.76 mm) malignant melanomas Am J Pathol 145 1994 510 514
26. J.L. Grem Fluorinated pyrimidines B.A. Chabner J.M. Collins Cancer chemotherapy: principles and practice 1990 Lippincott Philadelphia 180 224
27. G.B. Grindey, C. Shih, C.J. Barnett, H.L. Pearce, J.A. Engelhardt, G.C. Todd, S.M. Rinzel, J.F. Worzalla, L.S. Gossett, T.P. Everson, T.M. Wilson, M.E. Kobierski, M.A. Winter, J.R. Bewley, D. Kuhnt, E.C. Taylor, and R.G. Moran LY231514, a novel pyrrolopyrimidine antifolate that inhibits thymidylate synthase (TS) Proc Am Assoc Cancer Res 33 1992 411
28. D. Hanahan, and R.A. Weinberg The hallmarks of cancer Cell 100 2000 57 70
29. N. Hanna, F.A. Shepherd, F.V. Fossella, J.R. Pereira, F. De Marinis, J. von Pawel, U. Gatzemeier, T.C. Tsao, M. Pless, T. Muller, H.L. Lim, C. Desch, K. Szondy, R. Gervais, Shaharyar, C. Manegold, S. Paul, P. Paoletti, L. Einhorn, and P.A. Bunn Jr. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 229 2004 1589 1597
30. V. Heinemann, L.W. Hertel, G.B. Grindey, and W. Plunkett Comparison of the cellular pharmacokinetics and toxicity of 2′,2′- difluorodeoxycytidine and 1-beta-d-arabinofuranosylcytosine Cancer Res 48 1988 4024 4031
31. V. Heinemann, Y.Z. Xu, S. Chubb, A. Sen, L.W. Hertel, G.B. Grindey, and W. Plunkett Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine Mol Pharmacol 38 1990 567 572
32. L.W. Hertel, G.B. Boder, J.S. Kroin, S.M. Rinzel, G.A. Poore, G.C. Todd, and G.B. Grindey Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine) Cancer Res 50 1990 4417 4422
33. L.W. Hertel, J.S. Kroin, J.W. Misner, and J.M. Tustin Synthesis of 2-deoxy-2,2-difluoro-d-ribose and 2-deoxy-2,2-difluoro-d-ribofuranosyl nucleosides J Org Chem 53 1988 2406 2409
34. P. Huang, S. Chubb, L.W. Hertel, G.B. Grindey, and W. Plunkett Action of 2′,2′-difluorodeoxycytidine on DNA synthesis Cancer Res 51 1991 6110 6117
35. T. Johnson, L. Hammond, R. Johnson, R. Drengler, S.G. Eckhardt, J. Neumanitis, M. Villalona, T. Williams, S. Diab, J. Walling, C. Simmon, D.D. Von Hoff, and E. Rowinsky Phase I and pharmacokinetic study (PK) of the multitargeted antifol LY231514 (MTA) in combination with irinotecan (CPT-11) Proc Am Soc Clin Oncol 18 1999 172a
36. S.B. Kaye Gemcitabine: current status of phase I and II trials J Clin Oncol 12 1994 1527 1531
37. K.J. Kim, B. Li, J. Winer, M. Armanini, N. Gillett, H.S. Phillips, and N. Ferrara Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo Nature 362 1993 841 844
38. S. Laohavinij, S.R. Wedge, M.J. Lind, N. Bailey, A. Humphreys, M. Proctor, F. Chapman, D. Simmons, A. Oakley, L. Robson, L. Gumbrell, G.A. Taylor, H.D. Thomas, A.V. Boddy, D.R. Newell, and A.H. Calvert A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid Invest New Drugs 14 1996 325 335
39. D.W. Leung, G. Cachianes, W.J. Kuang, D.V. Goeddel, and N. Ferrara Vascular endothelial growth factor is a secreted angiogenic mitogen Science 246 1989 1306 1309
40. B. Linderholm, B. Tavelin, K. Grankvist, and R. Henriksson Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma J Clin Oncol 16 1998 3121 3128
41. B. Liu, H.M. Earl, D. Baban, M. Shoaibi, A. Fabra, D.J. Kerr, and L.W. Seymour Melanoma cell lines express VEGF receptor KDR and respond to exogenously added VEGF Biochem Biophys Res Commun 217 1995 721 727
42. J. Mattern, R. Koomagi, and M. Volm Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumor cell proliferation in human epidermoid lung carcinoma Br J Cancer 73 1996 931 934
43. A.C. McDonald, P.A. Vasey, L. Adams, J. Walling, J.R. Woodworth, T. Abrahams, S. McCarthy, N.P. Bailey, N. Siddiqui, M.J. Lind, A.H. Calvert, C.J. Twelves, J. Cassidy, and S.B. Kaye A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate Clin Cancer Res 4 1998 605 610
44. L.G. Mendelsohn, C. Shih, V.J. Chen, L.L. Habeck, S.B. Gates, and K.A. Shackelford Enzyme inhibition polyglutamation and the effect of LY231514 (MTA) on purine biosynthesis Semin Oncol 26 suppl 6 1999 42 47
45. R.L. Merriman, L.W. Hertel, R.M. Schultz, P.J. Houghton, J.A. Houghton, P.G. Rutherford, L.R. Tanzer, G.B. Boder, and G.B. Grindey Comparison of the antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung and pancreatic xenograft models Invest New Drugs 14 1996 243 247
46. B. Millauer, L.K. Shawver, K.H. Plate, W. Risau, and A. Ullrich Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant Nature 367 1994 576 579
47. A. Minchenko, T. Bauer, S. Salceda, and J. Caro Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo Lab Invest 71 1994 374 379
48. J.L. Misset, E. Gamelin, M. Campone, S. Delaloge, J.E. Latz, L. Bozec, and P. Fumoleau Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors Ann Oncol 15 2004 1123 1129
49. R.G. Moran, S.W. Baldwin, E.C. Taylor, and C. Shih The 6S- and 6R-diastereomers of 5, 10-dideaza-5, 6, 7, 8-tetrahydrofolate are equiactive inhibitors of de novo purine synthesis J Biol Chem 264 1989 21047 21051
50. C. Niyikiza, J. Walling, D. Thornton, D. Seitz, and R. Allen LY231514 (MTA): Relationship of vitamin metabolite profile to toxicity Proc Am Soc Clin Oncol 17 1998 558a
51. W. Plunkett, V. Gandhi, S. Chubb, B. Nowak, V. Heinemann, S. Mineishi, A. Sen, L.W. Hertel, and G.B. Grindey 2′,2′-difluorodeoxycytidine metabolism and mechanism of action in human leukemia cells Nucleosides & Nucleotides 8 1989 775 785
52. Richards DA, Kindler HL, Oettle H, Ramanathan R, Van Laethem J-L, Peeters M, Fuchs M, John W, Arning M, Von Hoff DD. A randomized phase III study comparing gemcitabine+pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas cancer. Journal of Clinical Oncology 2004; ASCO Annual Meeting Proceedings (Post-Meeting Edition); 22:14S (abstr 4007).
53. D.A. Rinaldi, H.A. Burris, F.A. Dorr, J.R. Woodworth, J.G. Kuhn, J.R. Eckardt, G. Rodriguez, S.W. Corso, S.M. Fields, and C. Langley Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation J Clin Oncol 13 1995 2842 2850
54. D.A. Rinaldi, J.G. Kuhn, H.A. Burris, F.A. Dorr, G. Rodriguez, S.G. Eckhardt, S. Jones, J.R. Woodworth, S. Baker, C. Langley, D. Mascorro, T. Abrahams, and D.D. Von Hoff A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation Cancer Chemother Pharmacol 44 1999 372 380
55. M. Saleh, S.A. Stacker, and A.F. Wilks Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence Cancer Res 56 1996 393 401
56. A.B. Sandler, J. Nemunaitis, C. Denham, J. von Pawel, Y. Cormier, U. Gatzemeier, K. Mattson, C. Manegold, M.C. Palmer, A. Gregor, B. Nguyen, C. Niyikiza, and L.H. Einhorn Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer J Clin Oncol 18 2000 122 130
57. 12 as front-line therapy in malignant pleural mesothelioma J Clin Oncol 21 2003 1556 1561
58. R.L. Schilsky Antimetabolites M.C. Perry The chemotherapy source book 1992 Williams & Wilkins Baltimore 301 315
59. R.M. Schultz, V.F. Patel, J.F. Worzalla, and C. Shih Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514 Anticancer Res 19 1999 437 443
60. C. Shih, V.J. Chen, L.S. Gossett, S.B. Gates, W.C. MacKellar, L.L. Habeck, K.A. Shackelford, L.G. Mendelsohn, D.J. Soose, V.F. Patel, S.L. Andis, J.R. Bewley, E.A. Rayl, B.A. Moroson, G.P. Beardsley, W. Kohler, M. Ratnam, and R.M. Schultz LY231514, a pyrrolo(2,3-d) pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes Cancer Res 57 1997 1116 1123
61. C. Shih, and D.E. Thornton Preclinical pharmacology studies and the clinical development of a novel multitargeted antifolate, MTA (LY231514) A.L. Jackman Antifolate drugs in cancer therapy 1999 Humana Press Totowa, New Jersey 183 201
62. M.A. Shipp, K.N. Ross, P. Tamayo, A.P. Weng, J.L. Kutok, R.C. Aguiar, M. Gaasenbeek, M. Angelo, M. Reich, G.S. Pinkus, T.S. Ray, M.A. Koval, K.W. Last, A. Norton, T.A. Lister, J. Mesirov, D.S. Neuberg, E.S. Lander, J.C. Aster, and T.R. Golub Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning Nat Med 8 2002 68 74
63. D. Shweiki, A. Itin, D. Soffer, and E. Keshet Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis Nature 359 1992 843 845
64. 12 and folate deficiency: a guide for the primary care physician Arch Intern Med 159 1999 1289 1298
65. T.T. Su, B. Guo, Y. Kawakami, K. Sommer, K. Chae, L.A. Humphries, R.M. Kato, S. Kang, L. Patrone, R. Wall, M. Teitell, M. Leitges, T. Kawakami, and D.J. Rawlings PKC-β control I B kinase lipid raft recruitment and activation in response to BCR signaling Nat Immunol 3 2002 780 786
66. Y. Takahashi, Y. Kitadai, C.D. Bucana, K.R. Cleary, and L.M. Ellis Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer Cancer Res 55 1995 3964 3968
67. E.C. Taylor, P.J. Harrington, S.R. Fletcher, G.P. Beardsley, and R.G. Moran Synthesis of the antileukemic agents 5,10-dideazaaminopterin and 5,10-dideaza-5,6,7,8-tetrahydroaminopterin J Med Chem 28 1985 914 921
68. E.C. Taylor, D. Kuhnt, C. Shih, S.M. Rinzel, G.B. Grindey, J. Barredo, M. Jannatipour, and R.G. Moran A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-l-glutamic acid, is an inhibitor of thymidylate synthase J Med Chem 35 1992 4450 4454
69. E.C. Taylor, and H.H. Patel Synthesis of pyrazolo(3,4,-d)pyrimidine analogues of the potent antitumor agent n-[4-(2-(2-amino-4(3h)-oxo-7h-pyrrolo(2, 3-d)pyrimidin-5yl)ethyl)benzoyl)]-l-glutamic acid (LY231514) Tetrahedron 48 1992 8089 8100
70. E.C. Taylor, and G.S.K. Wong Convergent and efficient palladium-effected synthesis of 5,10-dideaza-5,6,7,8-tetrahydrofolic acid (DDATHF) J Org Chem 54 1989 3618 3624
71. B.A. Teicher, E. Alvarez, K. Menon, M.A. Esterman, E. Considine, C. Shih, and M.M. Faul Antiangiogenic effects of a protein kinase Cβ-selective small molecule Cancer Chemother Pharmacol 49 2002 69 77
72. R. Thodtmann, H. Depenbrock, H. Dumez, J. Blatter, R.D. Johnson, A. van Oosterom, and A.R. Hanauske Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin J Clin Oncol 17 1999 3009 3016
73. N.J. Vogelzang, J.J. Rusthoven, J. Symanowski, C. Denham, E. Kaukel, P. Ruffie, U. Gatzemeier, M. Boyer, S. Emri, C. Manegold, C. Niyikiza, and P. Paoletti Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma J Clin Oncol 21 2003 2636 2644
74. M. Volm, R. Koomagi, and J. Mattern Interrelationships between microvessel density, expression of VEGF and resistance to doxorubicin of non-small lung cell carcinoma Anticancer Res 16 1996 213 217
75. H. von der Maase Gemcitabine in advanced bladder cancer Semin Oncol 28 suppl 7 2001 11 14
76. 12 balance and exhibit homocysteinemia Clin Res 39 1991 667a
77. N. Weidner, P. Carroll, J. Flax, W. Blumenfeld, and J. Folkman Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma Am J Pathol 143 1993 401 409
78. J.F. Worzalla, C. Shih, and R.M. Schultz Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate, LY231514 Anticancer Res 18 1998 3235 3239
79. E. Wu, R.C.T. Aguiar, K.J. Savage, J.L. Kutok, F. Wang, J.C. Aster, and M.A. Shipp PKC-β: a rational therapeutic target in diffuse large B-cell lymphoma Blood 100 2002 202a (abstr 757)
80. P. Xia, L.P. Aiello, H. Ishii, Z.Y. Jiang, D.J. Park, G.S. Robinson, H. Takagi, W.P. Newsome, M.R. Jirousek, and G.L. King Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth J Clin Invest 98 1996 2018 2026
81. H. Yoshiji, S. Kuriyama, D.K. Ways, J. Yoshii, Y. Miyamoto, M. Kawata, Y. Ikenaka, H. Tsujinoue, T. Nakatani, M. Shibuya, and H. Fukui Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis Cancer Res 59 1999 4413 4418
82. H.T. Zhang, P. Craft, P.A. Scott, M. Ziche, H.A. Weich, A.L. Harris, and R. Bicknell Enhancement of tumor growth and vascular density by transfection of vascular endothelial growth factor into MCF-7 human breast carcinoma cells J Natl Cancer Inst 87 1995 213 219